Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Being a long-term investor isn't always easy, as you'll inevitably encounter downturns as well as the thriving bull periods that occur in a cyclical market. However, this is a far better alternative ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

If your symptoms are serious or your doctor thinks something else is causing them, they might recommend a prescription medicine. Most people don't need any kind of treatment for mild cold symptoms.

Share on Pinterest GLP-1 drugs may improve brain and heart health but could cause problems for the kidneys and pancreas, according to a new study. FreshSplash/Getty Images Researchers report that ...

Sometimes you may receive a combination of therapies, or something else entirely. Oncology (cancer) drugs include a range of therapies and medications, such as chemotherapy drugs, targeted ...

Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for exceptional importation and sale are called "designated drugs".

Here’s how it works. When it comes to budget-friendly tablets, it’s impressive how many models strike the ideal balance between performance and affordability. This shows that not all the best ...

Copyright 2025 The Associated Press. All Rights Reserved. President Joe Biden speaks about prescription drug costs at the National Institutes of Health in Bethesda ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

They included popular blood thinners Xarelto and Eliquis and diabetes drugs Jardiance and Januvia. The savings from the new list prices for those drugs were expected to generate about $6 billion for ...

HHS told the Sec­ond Cir­cuit that Boehringer In­gel­heim’s vol­un­tary par­tic­i­pa­tion in Medicare ne­go­ti­a­tions “un­der­mines” its le­gal chal­lenge to the process.